All Phenotypes Yap1<tm1.1Dupa> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Yap1^tm1.1Dupa
targeted mutation 1.1, Duojia Pan
MGI:4819826

Summary

7 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Kras^tm4Tyj/Kras^tm4Tyj Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA	MGI:4819844
cn2	Lats1^tm1Noj/Lats1^tm1Noj Lats2^tm1.1Dupa/Lats2^tm1.1Dupa Wwtr1^tm1.2Eno/Wwtr1^tm1.2Eno Yap1^tm1.1Dupa/Yap1^tm1.1Dupa	involves: 129P2/OlaHsd * 129S/SvEv * 129S2/SvPas	MGI:5660349
cn3	Nf2^tm2Gth/Nf2^tm2Gth Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129P2/OlaHsd * C57BL/6 * DBA	MGI:4819842
cn4	Nf2^tm2Gth/Nf2^tm2Gth Yap1^tm1.1Dupa/Yap1⁺ Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129P2/OlaHsd * C57BL/6 * DBA	MGI:4819843
cn5	Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129P2/OlaHsd * C57BL/6 * DBA	MGI:4819841
cn6	Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Tg(Vil1-cre)997Gum/0	involves: 129P2/OlaHsd * C57BL/6J * SJL	MGI:4838643
cn7	Sav1^tm1.1Dupa/Sav1^tm1.1Dupa Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Tg(Vil1-cre)997Gum/0	involves: 129P2/OlaHsd * C57BL/6J * SJL	MGI:4838644

Allelic Composition	Kras^tm4Tyj/Kras^tm4Tyj Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Kras^tm4Tyj mutation (9 available); any Kras mutation (76 available)
Speer6-ps1^{Tg(Alb-cre)21Mgn} mutation (6 available); any Speer6-ps1 mutation (4 available)
Yap1^tm1.1Dupa mutation (2 available); any Yap1 mutation (37 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased hepatocellular carcinoma incidence ( J:162628 )

liver/biliary system

increased hepatocellular carcinoma incidence ( J:162628 )

Allelic Composition	Lats1^tm1Noj/Lats1^tm1Noj Lats2^tm1.1Dupa/Lats2^tm1.1Dupa Wwtr1^tm1.2Eno/Wwtr1^tm1.2Eno Yap1^tm1.1Dupa/Yap1^tm1.1Dupa
Genetic Background	involves: 129P2/OlaHsd * 129S/SvEv * 129S2/SvPas

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lats1^tm1Noj mutation (1 available); any Lats1 mutation (48 available)
Lats2^tm1.1Dupa mutation (1 available); any Lats2 mutation (42 available)
Wwtr1^tm1.2Eno mutation (0 available); any Wwtr1 mutation (23 available)
Yap1^tm1.1Dupa mutation (2 available); any Yap1 mutation (37 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

endocrine/exocrine glands

abnormal bile duct epithelium morphology ( J:223215 )

• slight proliferation of cryokeratin-positive biliary epithelial cells observed in liver following adenovirus expressing Cre recombinase (Ad-Cre) injection; in contrast to overproliferation found in homozygous Lats2^tm1.1Dupa Lats1^tm1Noj

liver/biliary system

abnormal bile duct epithelium morphology ( J:223215 )

enlarged liver ( J:223215 )

• mice develop slight hepatomegaly 8 weeks after Ad-Cre injection; in contrast to severe hepatomegaly developed by homozygous Lats2^tm1.1Dupa Lats1^tm1Noj

growth/size/body

enlarged liver ( J:223215 )

• mice develop slight hepatomegaly 8 weeks after Ad-Cre injection; in contrast to severe hepatomegaly developed by homozygous Lats2^tm1.1Dupa Lats1^tm1Noj

Allelic Composition	Nf2^tm2Gth/Nf2^tm2Gth Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2^tm2Gth mutation (3 available); any Nf2 mutation (65 available)
Speer6-ps1^{Tg(Alb-cre)21Mgn} mutation (6 available); any Speer6-ps1 mutation (4 available)
Yap1^tm1.1Dupa mutation (2 available); any Yap1 mutation (37 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

liver/biliary system phenotype ( J:162628 )

N	• liver is as enlarge as in Nf2^tm2Gth/Nf2^tm2Gth Tg(Alb-cre)21Mgn mice • bile over-proliferation observed in Nf2^tm2Gth/Nf2^tm2Gth Tg(Alb-cre)21Mgn mice is suppressed

neoplasm

neoplasm ( J:162628 )

N	• mice do not develop bile duct hamartomas or hepatocellular carcinoma unlike Nf2^tm2Gth/Nf2^tm2Gth Tg(Alb-cre)21Mgn mice

Allelic Composition	Nf2^tm2Gth/Nf2^tm2Gth Yap1^tm1.1Dupa/Yap1⁺ Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

liver/biliary system phenotype ( J:162628 )

N	• mice do not exhibit bile duct proliferation

enlarged liver ( J:162628 )

• slightly

neoplasm

neoplasm ( J:162628 )

N	• mice do not develop bile duct hamartomas or hepatocellular carcinoma

growth/size/body

enlarged liver ( J:162628 )

• slightly

Allelic Composition	Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Speer6-ps1^{Tg(Alb-cre)21Mgn} mutation (6 available); any Speer6-ps1 mutation (4 available)
Yap1^tm1.1Dupa mutation (2 available); any Yap1 mutation (37 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

growth/size/body

enlarged liver ( J:162628 )

liver/biliary system

increased hepatocyte apoptosis ( J:162628 )

• at 1 to 2 months

increased hepatocyte proliferation ( J:162628 )

abnormal bile duct morphology ( J:162628 )

• after 30 weeks, mice lack bile ducts or bile duct-like structures unlike wild-type mice

abnormal bile duct development ( J:162628 )

• livers fail to form mature bile ducts unlike in wild-type mice

enlarged liver ( J:162628 )

abnormal hepatocyte morphology ( J:162628 )

• at 1 to 2 months, the liver contains multiple areas of injured hepatocytes unlike in wild-type mice

macrovesicular hepatic steatosis ( J:162628 )

liver cirrhosis ( J:162628 )

liver fibrosis ( J:162628 )

• mice exhibit progressive liver fibrosis with early periportal fibrosis at 20 weeks unlike wild-type mice

• at 30 weeks, mice exhibit advanced fibrosis with cirrhosis unlike wild-type mice

pale liver ( J:162628 )

homeostasis/metabolism

increased circulating bilirubin level ( J:162628 )

increased circulating alanine transaminase level ( J:162628 )

endocrine/exocrine glands

abnormal bile duct morphology ( J:162628 )

• after 30 weeks, mice lack bile ducts or bile duct-like structures unlike wild-type mice

abnormal bile duct development ( J:162628 )

• livers fail to form mature bile ducts unlike in wild-type mice

cellular

increased hepatocyte apoptosis ( J:162628 )

• at 1 to 2 months

increased hepatocyte proliferation ( J:162628 )

Allelic Composition	Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Tg(Vil1-cre)997Gum/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6J * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Vil1-cre)997Gum mutation (2 available)
Yap1^tm1.1Dupa mutation (2 available); any Yap1 mutation (37 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:165471 )

• in DSS-treated mice

digestive/alimentary system

digestive/alimentary phenotype ( J:165471 )

N	• mice, whether treated with DSS or not, do not develop colonic polyps

increased enterocyte apoptosis ( J:165471 )

• in DSS-treated mice

abnormal enterocyte proliferation ( J:165471 )

• DSS-treated mice exhibit decreased cell proliferation in the colon compared with similarly treated wild-type mice

increased susceptibility to induced colitis ( J:165471 )

• DSS-treated mice exhibit increased mortality a rapid decrease in body weight, increased apoptotic cells in the colon, and decreased proliferating cells in the colon compared with similarly treated wild-type mice

immune system

increased susceptibility to induced colitis ( J:165471 )

homeostasis/metabolism

increased susceptibility to xenobiotic induced morbidity/mortality ( J:165471 )

• in DSS-treated mice

growth/size/body

increased susceptibility to weight loss ( J:165471 )

• in DSS-treated mice

cellular

increased enterocyte apoptosis ( J:165471 )

• in DSS-treated mice

abnormal enterocyte proliferation ( J:165471 )

• DSS-treated mice exhibit decreased cell proliferation in the colon compared with similarly treated wild-type mice

Allelic Composition	Sav1^tm1.1Dupa/Sav1^tm1.1Dupa Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Tg(Vil1-cre)997Gum/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6J * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sav1^tm1.1Dupa mutation (1 available); any Sav1 mutation (20 available)
Tg(Vil1-cre)997Gum mutation (2 available)
Yap1^tm1.1Dupa mutation (2 available); any Yap1 mutation (37 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

digestive/alimentary system

digestive/alimentary phenotype ( J:165471 )

N	• mice exhibit normal cell proliferation in the small intestine and colon • mice, whether treated with DSS or not, do not develop colonic polyps

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 05/07/2024 MGI 6.23